Literature DB >> 19765331

No evidence of transmission of H5N1 highly pathogenic avian influenza to humans after unprotected contact with infected wild swans.

A Wallensten1, M Salter, S Bennett, I Brown, K Hoschler, I Oliver.   

Abstract

Highly pathogenic avian influenza (HPAI) subtype H5N1 remains a public health threat as long as it circulates in wild and domestic birds. Information on the transmissibility of H5N1 HPAI from wild birds is needed for evidence-based public health advice. We investigated if transmission of H5N1 HPAI had taken place in people that had unprotected contact with infected wild mute swans during an incident at the Abbotsbury Swannery in Dorset, England. Thirteen people who had been exposed to infected swans were contacted and actively followed up for symptoms. Serology was taken after 30 days. We did not find evidence of transmission of H5N1 HPAI to humans during the incident. The incident provided a rare opportunity to study the transmissibility of the virus from wild birds to humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19765331     DOI: 10.1017/S0950268809990811

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  3 in total

1.  Assessment of serosurveys for H5N1.

Authors:  Eric S Toner; Amesh A Adalja; Jennifer B Nuzzo; Thomas V Inglesby; Donald A Henderson; Donald S Burke
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

2.  The response of mute swans (Cygnus olor, Gm. 1789) to vaccination against avian influenza with an inactivated H5N2 vaccine.

Authors:  Beata Dolka; Artur Żbikowski; Izabella Dolka; Piotr Szeleszczuk
Journal:  Acta Vet Scand       Date:  2016-10-22       Impact factor: 1.695

3.  Serological evidence of human infections with highly pathogenic avian influenza A(H5N1) virus: a systematic review and meta-analysis.

Authors:  Xinhua Chen; Wei Wang; Yan Wang; Shengjie Lai; Juan Yang; Benjamin J Cowling; Peter W Horby; Timothy M Uyeki; Hongjie Yu
Journal:  BMC Med       Date:  2020-12-02       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.